Anaptys已顺利完成旗下First Tracks Biotherapeutics业务板块的分拆工作。此次重组后，公司将集中资源独立运营与葛兰素史克（GSK）及Vanda制药的财务合作项目。通过战略调整，Anaptys进一步聚焦核心业务领域，为未来研发管线的优化奠定基础。
Anaptys已顺利完成旗下First Tracks Biotherapeutics业务板块的分拆工作。此次重组后，公司将集中资源独立运营与葛兰素史克（GSK）及Vanda制药的财务合作项目。通过战略调整，Anaptys进一步聚焦核心业务领域，为未来研发管线的优化奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.